Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …

Antibiotics have been a cornerstone of modern medicine and have saved millions of lives.
The use of antibiotics in the clinic has made many complicated procedures and treatment …

The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections due to …

One of the greatest achievements of modern medicine is the development of antibiotics
against life-threatening infections, but the emergence of multidrug-resistant (MDR) gram …

Hospital-acquired infections due to multidrug-resistant Gram-negative bacteria constitute
major health problems, since the medical community is continuously running out of available …

The emergence of multidrug-resistant gram-negative bacteria and the lack of new antibiotics
to combat them have led to the revival of polymyxins, an old class of cationic, cyclic …

Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …

Polymyxin B and colistin (polymyxin E) are polypeptide antibiotics that were developed in
the 1940s, but fell into disfavor due to their high toxicity rates. These two antibiotics were …

Polymyxins have re-emerged in clinical practice owing to the dry antibiotic development
pipeline and worldwide increasing prevalence of nosocomial infections caused by multidrug …

'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …